Paulson & Co Keeps Adding to His Bausch Health Stake: Should Investors See Eye to Eye With Him?

What do you call it when a billionaire famous for shorting the entire U.S. housing market suddenly keeps buying millions of shares of a beaten-down pharmaceutical company trading at $6? 👀💊💸

A hobby?
A hunch?
A hedge-fund fever dream?

Or… something you might want to take a closer look at? 👀

Enter John Paulson, legendary investor, destroyer of subprime mortgages, and proud owner of 19% of Bausch Health Companies (NYSE: BHC). Yes — nineteen percent. At this point, he practically gets his own parking spot at headquarters.

Let’s break it down.

🧠 Trigger #1: Paulson & Co Is Buying Like He Can See the Future

Not one buy.
Not two buys.
Not even three.

Paulson & Co has been buying BHC shares all year long, scooping up millions and millions of shares at prices ranging from $5 to $9 like it’s an early-2000s Black Friday sale at Best Buy.

Most recent transaction?
2.5 million shares at $6.25, on November 25, 2025.

When a billionaire with a Harvard MBA, a legendary career, and a net worth north of $3B keeps backing up the truck… you pay attention. 🚚💰

His firm now owns 73 million shares. That’s 19% of the company.

This isn’t nibbling. This is a buffet.

🏛️ Trigger #2: Institutions Are In — With Room for More

Institutions hold:

• 66% of shares outstanding

• 74% of the float

That’s solid — and leaves room for further accumulation if sentiment turns.

Top dogs include:

• Paulson & Co — 19.1%

• Goldentree — 9.4%

• Nomura — 4.2%

• HOOPP — 3.5%

• Vanguard — 3.3%

• RBC — 2.8%

This is not a random penny-stock crowd. These are big, serious, spreadsheet-loving, PowerPoint-eating institutions.

For Bausch Health (BHC)'s Institutional Ownership breakdown, 🔍 see here.

🐻 Trigger #3: Almost No Short Sellers — Bears Hibernating at 2%

Short interest?
Just 2.05%.

Translation:
The market is not lining up to bet against BHC. 🐻💤

Either:

1. Bears are scared,

2. Bears forgot the ticker, or

3. Bears looked at Paulson owning 19% and said, “You know what? I’m good.”

🧪 Trigger #4: Analysts Are… Neutral. And Honestly That’s a Win.

Analyst consensus: Hold.
Not a screaming buy. Not a flamethrower sell.

Call it “Wait-and-see.”

Why?

• Recent results were strong

• But regulatory overhangs (especially around blockbuster drug Xifaxan) keep analysts cautious

• Debt remains heavy, and BHC’s balance sheet is… robustly leveraged, let’s say 💣💼

Sometimes “Hold” just means:
“We have no idea what Paulson sees, but we’re not arguing with him.”

📈 Trigger #5: The Business Is Actually Performing

Q3 2025 was strong, and not in a “participation trophy” way.
More like: “Oh wait, Bausch still knows how to run a business?”

• Revenue up 7% (5% organic)

• GAAP Net Income: $179M (vs loss last year)

• Adjusted EBITDA: $986M, up 8%

Segment highlights:

• Salix (GI drugs): +12%

• Solta Medical (aesthetics): +25%

• Bausch + Lomb: +7%

• International and Diversified were a bit soft, but overall momentum is there.

CEO Thomas Appio is essentially saying:
“We’re executing. We’re growing. And we’re not sleeping at night because we’re also paying off debt.”

💰 Debt: Heavy? Yes. Manageable? Paulson Seems to Think So.

BHC’s debt is the elephant in the room. Actually, no — it’s the elephant, the living room, and possibly the entire zoo. 🐘🏢

• Total debt: $21B

• Debt-to-equity: 59 (not a typo)

• Interest coverage ratio: 1.4x (tight!)

But management has been refinancing, repaying, restructuring, and doing everything short of selling snacks at halftime to raise cash.

They recently:

• Redeemed $600M in notes

• Cancelled a $300M financing facility

• Generated $405M in quarterly operating cash flow

• Are expecting improved cash flow next year

This is the “high-risk, high-reward, drink-coffee-before-analyzing-this” bucket of stocks.

 👉 Want the full picture? Dive into Bausch Health (BHC)'s financials here.

📉 Valuation: This Thing Is Dirt Cheap (For Reasons) 😅

Let’s talk numbers that will either excite you or scare you:

• Forward P/E: 1.49

• Price/Sales: 0.24

• EV/EBITDA: 6.7

This stock is priced like it’s going out of business.
But the company is… not going out of business.

It’s growing, deleveraging (slowly), and generating cash.

This is what we call:
“The deep value aisle behind the deep value aisle.”

🔭 The Bull Case — Why Paulson Might Be Right

Investors bullish on BHC point to:

🔥 1. Strong product performance

Xifaxan, Cabtreo, and aesthetics devices (Thermage/Fraxel) are doing well.

🚀 2. R&D pipeline improvements

Especially in hepatology (new drugs for alcohol-associated hepatitis coming).

💰 3. Cash flow improving + profitability swing

The company is printing earnings again.

💎 4. Valuation so low it might be illegal in some states

📦 5. Asset unlock potential

Bausch + Lomb remains a giant value lever.

🐢 The Bear Case — Because Every Story Has One

💣 1. Huge debt load

No surprise here.

📉 2. Execution risk

Debt reduction requires consistent performance.

⚖️ 3. Regulatory risk

Especially around gastrointestinal drugs.

🧪 4. Product concentration

Xifaxan alone carries meaningful risk.

🌪 5. Volatility

This thing moves like it’s had three espresso shots.

💡💡💡 Curious about another deep oil exploration play?
Check our takes on UnitedHealth Group or even Oscar Health.

📌 Funanc1al TL;DR (Quick Take)

• Billionaire investor buying relentlessly: Paulson = bullish

• Institutions: in

• Shorts: barely exist

• Earnings: solid

• Balance sheet: “Yikes” but trending better

• Valuation: cheap enough to make a value investor blush

• Risk level: High

• Potential reward: Also high

This is not your grandmother’s safe stock.
This is a speculation with upside — and a storyline.

❓ FAQ

Is BHC a value stock or a turnaround play?

Both. And possibly an adventure.

Why is the stock so cheap?

Debt. Regulatory concerns. History.
But fundamentals are improving.

Why is Paulson buying so aggressively?

Either he sees future value — or the man just really loves gastrointestinal drugs.

Is this a safe long-term investment?

No.
But it could be a lucrative speculative one.

🧾⚠️📢 Fun(anc1al) but Serious Disclaimer: 🧾⚠️📢

This article is research and entertainment, not a prescription. Consult a financial professional before investing. Bausch Health may improve your portfolio or cause side effects including volatility, confusion, and spontaneous Googling of “what is EBITDA?”. Invest carefully.   

Nothing here is financial advice—unless laughter compounds, in which case, you’re already profiting. 🥫😂

Always DYOR, hold the FOMO, and don’t invest what you can’t afford to lose.

Keep your humor cells alive. We laugh, we analyze, we meme. We sell jokes and opinions — and yes, we’re billing your sense of humor. 🎪💸  We’re not financial advisors. We’re FUNancial advisors.

Invest at your own risk. 💸⚠️💸

🧭 Want More Like This?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside
• 🧟 Corporate Resurrection Series — Our special series on companies rising from the financial grave. 🎯 The “Turnaround or Toast” Series (If it still exists. We’re not sure. Ask the intern.)
• 📈 Biotech Bets & Innovation Radar (Problem is we can't detect the Radar)

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny